![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
There are 5 million persons suffering from asthma in Great Britain and despite medication, half a million of these persons have symptoms which limit their daily life. In some serious cases, the asthma develop may into a life-threatening condition. An extensive research study involving Airsonett has been initiated in Great Britain. The trial is being funded by the National Institute for Health Research Health Technology Assessment programme (NIHR).
The trial will include 222 adult participants with severe allergic asthma that is poorly controlled despite high intensity treatment. Participants will receive 12 months of treatment with the Airsonett in addition to standard asthma care in accordance with BTS/SIGN guidance. The clinical trial, being led by Professor Anoop J Chauhan, Professor of Respiratory Medicine at the Queen Alexandra Hospital in Portsmouth, is investigating whether treatment with Temperature-controlled Laminar Airflow (TLA), Airsonett, is able to reduce the frequency of severe asthma exacerbations in patients with severe allergic asthma. The trial will also assess how the treatment is affecting their asthma control, quality of life and workplace productivity.
The LASER trial (Laminar Airflow in Severe Asthma for Exacerbation Reduction) is a multi-centre randomised, double blind, placebo controlled trial. It is being delivered at a number of centres in the UK with experience of treating patients with severe asthma and experience of clinical research in asthma. There are currently five trial centres; Portsmouth, Southampton, Leicester, Birmingham and Liverpool.
We are very pleased over the interest in Airsonett in the British health care sector. We already know that Airsonett drastically reduces the level of allergens inhaled during night-time sleep and gives the asthmatic’s hyperactive immune system long and regular periods of recovery. The results of the LASER trial, which is fully funded by NIHR, will facilitate for Airsonett to play a role in the treatment of asthma in Great Britain. I am also convinced that the results from LASER will be very valuable in our contacts with doctors and authorities on other markets, says Fredrik Werner, CEO, Airsonett AB.
Airsonett markets a treatment for patients with atopic (allergic) asthma who, in spite of taking asthma medication, still has poorly controlled asthma. The treatment has no side effects. The Airsonett treatment ensures that the patient sleeps in clean air. Studies show that Airsonett inhibits the allergy, reduces the inflammation and improves quality of life.
About Airsonett
Airsonett is a treatment for patients who, in spite of taking asthma medication, still have poorly controlled asthma. The treatment has no side effects. Airsonett creates an allergen free zone in the patient’s breathing zone. The patient sleeps in clean air which inhibits the allergy, reduces the inflammation and improves quality of life. Airsonett has undergone rigorous clinical research as well as health economy studies and has obtained the necessary regulatory approvals in Europe and the US. A number of health care institutions in various countries provide Airsonett treatment free of charge for the group of patients most suited for Airsonett. Airsonett AB is a Swedish-owned company. The main share owners are SEB Venture Capital, Industrifonden and Magnus Lundberg.
